Írsko - angličtina - HPRA (Health Products Regulatory Authority)

norbrook laboratories (ireland) limited - fipronil; (s)-methopene - spot-on solution - 67/60.3 mg/pipette - fipronil, combinations

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

norbrook laboratories (ireland) limited - fipronil; (s)-methoprene - spot-on solution - 67, 60.3 mg/pipette - fipronil, combinations

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

norbrook laboratories (ireland) limited - fipronil; (s)-methoprene - spot-on solution - 67, 60.3 mg/pipette - fipronil, combinations

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

norbrook laboratories (ireland) limited - fipronil; (s)-methoprene - spot-on solution - 67, 60.3 mg/pipette - fipronil, combinations

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

bimeda animal health limited - dimpylate - concentrate for dip solution - 60 percent weight/weight - organophosphorous compounds

Spojené štáty - angličtina - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - fluocinonide (unii: 2w4a77ypan) (fluocinonide - unii:2w4a77ypan) - fluocinonide cream usp, 0.05% (emollient base) is intended for topical administration. the active component is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)],(6α,11β,16α)–. it has the following chemical structure: fluocinonide cream usp, 0.05% (emollient base) contains fluocinonide 0.5 mg/g in a water-washable aqueous emollient base of cetyl alcohol, citric acid (anhydrous), mineral oil, polysorbate 60, propylene glycol, sorbitan monostearate, stearyl alcohol and purified water.

Spojené štáty - angličtina - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below. ciprofloxacin is indicated in adult patients for treatment of urinary tract infections caused by escherichia coli , klebsiella pneumoniae , enterobacter cloacae , serratia marcescens , proteus mirabilis , providencia rettgeri , morganella morganii , citrobacter koseri , citrobacter freundii , pseudomonas aeruginosa , methicillin-susceptible staphylococcus epidermidis , staphylococcus saprophyticus , or enterococcus faecalis . ciprofloxacin is indicated in adult female patients for treatment of acute uncomplicated cystitis caused by escherichia coli or staphylococcus saprophyticus. ciprofloxacin is indicated in

Spojené štáty - angličtina - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole tablets are indicated for the treatment of parkinson's disease. ropinirole tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole hydrochloride is contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. pregnancy category c. there are no adequate and well-controlled studies in pregnant women. in animal reproduction studies, ropinirole has been shown to have adverse effects on embryo-fetal development, including teratogenic effects. ropinirole hydrochloride should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. oral treatment of pregnant rats with ropinirole during organogenesis resulted in decreased fetal body weight, increased fetal death, and digital malformations at 24, 36, and 60 times, respectively, the maximum recommended human dose (mrhd) for parkinson's disease (24 mg/day)

Spojené štáty - angličtina - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [ see clinical studies ( 14.1) ]. meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [ see clinical studies ( 14.1) ]. meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients who weigh ≥60 kg [ see dosage and administration ( 2.4) and clinical studies ( 14.2) ]. meloxicam tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product [ see warnings and precautions ( 5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reac

Spojené štáty - angličtina - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - meloxicam (unii: vg2qf83cgl) (meloxicam - unii:vg2qf83cgl) - meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis [ see clinical studies ( 14.1) ]. meloxicam tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis [ see clinical studies ( 14.1) ]. meloxicam tablets are indicated for relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients who weigh ≥60 kg [ see dosage and administration ( 2.4) and clinical studies ( 14.2) ]. meloxicam tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product [ see warnings and precautions ( 5.7, 5.9) ] - history of asthma, urticaria, or other allergic-type reac